|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C12Q 1/6886 | |
| G01N 33/574 | |||
| C12N 9/12 | |||
| A61P 35/00 | |||
| A61P 35/02 | |||
| A61P 35/04 |
| (11) | Patento numeris | 3333259 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 17201390.6 |
| Europos patento paraiškos padavimo data | 2011-06-09 | |
| (97) | Europos patento paraiškos paskelbimo data | 2018-06-13 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2021-02-24 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 352959 P | 2010-06-09 | US |
| (72) |
GARRAWAY, Levi, A., US
EMERY, Caroline, US
WAGLE, Nikhil, US
|
| (73) |
Dana Farber Cancer Institute, Inc.,
450 Brookline Avenue, Boston, Massachusetts 02215,
US
|
| (54) | A MEK1 MUTATION CONFERRING RESISTANCE TO RAF AND MEK INHIBITORS |
| A MEK1 MUTATION CONFERRING RESISTANCE TO RAF AND MEK INHIBITORS |